Merita Rumano

Merita Rumano

Auto-generated profile, based on publicly available information

Merita Rumano

Department of Biology, Faculty of Natural Sciences University of Tirana Tirana Albania

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 August 2025 in British Journal of Clinical Pharmacology
Verified
Journal Article
Open access
Guenka PetrovaGuenka Petrova
Guenka Petrova
SBStiliyana Blagova
Stiliyana Blagova
KTKonstantin Tachkov
Konstantin Tachkov
MSMarlene Santos
Marlene Santos
JBJames Bluett
James Bluett
DMDenis Mulleman
Denis Mulleman
Aims: To evaluate available information on therapeutic drug monitoring (TDM) education programmes and their implementation across different countries. Methods: The study was performed in two phases. First, a scoping review of scientific literature on available education programmes was performed. Afterwards, a questionnaire was distributed among a worldwide network of professionals engaged in the practice of TDM. Results: Eight scientific articles discussing TDM educational programmes were found. They described in depth an educational programme on TDM, which was primarily offered as postgraduate education programme for hospital staff. We received a total 23 responses (30% response rate); of these, 68% were from academia. For 70% of respondents, TDM is part of the educational programme of healthcare professionals, and for 56% it is offered at both undergraduate and postgraduate level, aimed mainly at physicians (39%) and pharmacists (65%). TDM is mainly performed in infectious diseases (n = 15), neurology (n = 14) and psychiatry (n = 12), as well as for antibiotics (83%), monoclonal antibodies (53%), and oncology and psychotropics (48%). Funding for TDM is derived mostly from public health insurance (48%), hospital (44%), patients (39%). In some cases, patients might co‐pay to hospital or to health insurance fund. Conclusions: Education on TDM is scattered across different subjects, disciplines and degrees. It is oriented essentially towards physicians and pharmacists, and its funding is mainly public. General guidelines are lacking. In light of this, it is necessary to consider developing a comprehensive educational programme on TDM, oriented towards relevant drugs and diseases, and encompassing appropriate analytical and pharmacological methods.

19 June 2026 in Clinical and Translational Science
Verified
Journal Article
Open access
KTKonstantin Tachkov
Konstantin Tachkov
MRMerita Rumano
Merita Rumano
JBJames Bluett
James Bluett
NBNataša Bogavac‐Stanojević
Nataša Bogavac‐Stanojević
EDErwin Dreesen
Erwin Dreesen
DMDenis Mulleman
Denis Mulleman
Treatment of chronic inflammatory diseases has been revolutionized with the introduction of targeted therapies using therapeutic antibodies. However, a large proportion of patients do not respond to treatment, or they lose response over time. To overcome this challenge, researchers have started to investigate strategies for treatment optimization, based on the development of patient stratification tools and therapeutic drug monitoring (TDM). The aim of the COST Action European Network on Optimizing Treatment with Therapeutic Antibodies in chronic inflammatory diseases (ENOTTA) is to create an interdisciplinary, pan‐European network to defragment and structure scientific research in this field. Through the network, ENOTTA will facilitate the implementation of tools for patient stratification, as well as individualized (TDM‐guided) approaches. These strategies should be cost‐effective and provide therapeutic antibody treatment optimization for the treatment of chronic inflammatory diseases. This article highlights the key achievements of the ENOTTA consortium to date.

28 October 2022 in Agronomy Science
Verified
Journal Article
Open access
ADAida Dervishi
Aida Dervishi
MRMerita Rumano
Merita Rumano
PRPanajota Ruzi
Panajota Ruzi
AÇAdriatik Çakalli
Adriatik Çakalli
The genetic diversity and variation in crude protein content among eleven wheat genotypes, comprising three elite local genotypes and eight wheat genotypes of foreign origin were investigated in the present study. Variability was evidenced in grain protein content estimated by biuret test, it ranged from 9.5 to 13.9% with mean of 11.58%. Comparative analysis between local and introduced wheat genotypes revealed that the local genotypes had lower protein content than those of foreign origin. Fourteen polymorphic RAPD markers were used to assess genetic diversity among selected wheat varieties. The mean similarity among wheat genotypes was 67%. Genetic similarity among local wheat varieties was higher (83%) than among those of foreign origin (66%). The wheat genotypes were grouped into two main clusters on UPGMA dendrogram constructed based on Dice similarity coefficients. A clear clustering of genotypes according to the origin wasobserved. This clustering was also supported by principal coordinate analysis (PCoA) results. There was no observed clustering based on the protein content. The data revealed that local wheat genetic had narrow genetic diversity, however the wheat genotypes of foreign origin constitute a promising material to be employed in breeding programs aiming the increase of wheat protein content and genetic diversity.